Jeffrey Gudin's most recent trade in Virpax Pharmaceuticals Inc was a trade of 50,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 25, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Virpax Pharmaceuticals Inc | Jeffrey Gudin | Director, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Virpax Pharmaceuticals Inc | Jeffrey Gudin | Director, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 60,676 | 60,676 | - | - | Stock Option (right to buy) | |
| Virpax Pharmaceuticals Inc | Jeffrey Gudin | Director, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) |